{
    "clinical_study": {
        "@rank": "129606", 
        "arm_group": [
            {
                "arm_group_label": "KHK6640", 
                "arm_group_type": "Experimental", 
                "description": "KHK6640"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of\n      KHK6640, given as a single dose and as multiple doses in patients with Prodromal Alzheimer's\n      Disease (AD) or Mild to Moderate AD."
        }, 
        "brief_title": "A Study of Single and Multiple Doses of KHK6640 in Subjects With Prodromal or Mild to Moderate Alzheimer's Disease", 
        "completion_date": {
            "#text": "February 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Alzheimer's Disease", 
        "condition_browse": {
            "mesh_term": "Alzheimer Disease"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with prodromal AD or mild to moderate AD\n\n          -  Clinical Dementia Rating (CDR) score of 0.5, 1.0, or 2.0\n\n          -  Have a cognitive impairment\n\n          -  Low A\u03b2 and high Tau in Cerebrospinal fluid (CSF)\n\n          -  Mini Mental State Examination (MMSE) score > 16 at Screening\n\n        Exclusion Criteria:\n\n          -  Previous active treatment with an AD immunotherapy in an investigational study\n\n          -  Use of another investigational drug within 30 days of screening\n\n          -  History or presence of clinically significant seizures, brain trauma, transient\n             ischemic attack, and/or cerebrovascular disease\n\n          -  Presence of a neurological condition that could be contributing to cognitive\n             impairment above and beyond that caused by the subject's AD\n\n          -  Evidence of infection, tumor, or other clinically significant lesions that could\n             indicate a dementia diagnosis other than AD"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "55 Years"
        }, 
        "enrollment": {
            "#text": "62", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 24, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02127476", 
            "org_study_id": "6640-001", 
            "secondary_id": "2013-002873-23"
        }, 
        "intervention": [
            {
                "arm_group_label": "KHK6640", 
                "description": "Single ascending dose and multiple ascending doses administration", 
                "intervention_name": "KHK6640", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Single ascending dose and multiple ascending doses administration", 
                "intervention_name": "Matching Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 28, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Gent", 
                        "country": "Belgium", 
                        "zip": "9000"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Leuven", 
                        "country": "Belgium", 
                        "zip": "3000"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Turku", 
                        "country": "Finland"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany", 
                        "zip": "14050"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mannheim", 
                        "country": "Germany", 
                        "zip": "D-68159"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Amsterdam", 
                        "country": "Netherlands"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Groningen", 
                        "country": "Netherlands"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Zwolle", 
                        "country": "Netherlands"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Malm\u00f6", 
                        "country": "Sweden"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "M\u00f6lndal", 
                        "country": "Sweden"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Stockholm", 
                        "country": "Sweden"
                    }
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Belgium", 
                "Finland", 
                "Germany", 
                "Netherlands", 
                "Sweden"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 1 Double-blind, Placebo-controlled, Single- and Multiple-ascending-dose Study of KHK6640 in Alzheimer's Disease", 
        "overall_contact": {
            "email": "clinical.info@kyowa-kirin-pharma.com", 
            "last_name": "Project Leader", 
            "phone": "+1 609-919-1100"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "Sweden: Medical Products Agency", 
                "Germany: Paul-Ehrlich-Institut", 
                "Finland: Finnish Medicines Agency", 
                "Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)", 
                "Belgium: Federal Agency for Medicines and Health Products, FAMHP"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Safety assessment variables will include all adverse events (AEs) including serious and non-serious AEs, laboratory parameters (hematology, chemistry, and urinalysis), vital signs, 12-lead electrocardiograms, physical and neurological examinations, and brain MRI", 
            "measure": "Number of Participants with Adverse Events as a Measure of Safety and Tolerability", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 7 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02127476"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Kyowa Hakko Kirin Pharma, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Kyowa Hakko Kirin Pharma, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}